Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

14 janv. 2026 13h14 HE | Source: Asthma and Allergy Foundation of America

Amid COVID-19 Vaccine Confusion, New Tool Helps Guide Decision-Making

Washington, DC, Jan. 14, 2026 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) announces the release of a new COVID-19 Vaccine Decision Aid, designed to help people...
14 janv. 2026 08h00 HE | Source: Unity Consortium

Statement from Unity Consortium on Announced Changes to the U.S. Childhood and Adolescent Immunization Schedule

Statement from Unity Consortium on Announced Changes to the U.S. Childhood and Adolescent Immunization Schedule
08 janv. 2026 16h34 HE | Source: Asthma and Allergy Foundation of America

AAFA Affirms Public Health Value of Vaccines as Nearly Everyone Is High Risk or Lives in Community with High Risk Individuals

Washington, DC, Jan. 08, 2026 (GLOBE NEWSWIRE) -- On January 5, 2026, under Health and Human Services Secretary Kennedy’s leadership, the Centers for Disease Control and Prevention (CDC) released...
08 janv. 2026 16h05 HE | Source: Asthma and Allergy Foundation of America

AAFA Affirms Public Health Value of Vaccines as Nearly Everyone Is High Risk or Lives in Community with High Risk Individuals

Washington, DC, Jan. 08, 2026 (GLOBE NEWSWIRE) -- On January 5, 2026, under Health and Human Services Secretary Kennedy’s leadership, the Centers for Disease Control and Prevention (CDC) released...
07 janv. 2026 08h01 HE | Source: Vaxxas Pty Ltd

Vaxxas Appoints Former Merck Global Vaccines President David Peacock as CEO

BRISBANE, Australia and CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Vaxxas Pty Ltd today announced the appointment of global biopharmaceutical executive Mr David Peacock as Chief Executive...
22 déc. 2025 02h17 HE | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag SVF Vaccines planerar notering på Nasdaq First North Premier genom ett omvänt förvärv inför accelererad vaccinutveckling

STOCKHOLM, 22 december 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget SVF Vaccines AB har ingått en icke-bindande avsiktsförklaring med Novakand Pharma AB...
22 déc. 2025 02h17 HE | Source: Karolinska Development AB (publ)

Karolinska Development’s portfolio company SVF Vaccines plans for listing on Nasdaq First North Premier through reverse takeover ahead of accelerated vaccine development

STOCKHOLM, Sweden, December 22, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company SVF Vaccines has signed a non-binding letter of intent (LOI) with Novakand...
14 déc. 2025 08h01 HE | Source: Vaxxas Pty Ltd

Vaxxas Secures TGA Licence to Manufacture Therapeutic Goods

BRISBANE, Australia and CAMBRIDGE, Mass., Dec. 14, 2025 (GLOBE NEWSWIRE) -- Australian biotechnology pioneer Vaxxas Pty Ltd, has been granted a licence by the Therapeutic Goods Administration...
26 nov. 2025 07h13 HE | Source: Research and Markets

Infectious Vaccine Collaboration and Licensing Agreements Trends Analysis Report 2025 with Directory of 543 Deals Signed Since 2016 by Company A-Z, Therapy Focus and Technology Type

Dublin, Nov. 26, 2025 (GLOBE NEWSWIRE) -- The "Infectious Vaccine Collaboration and Licensing Deals 2016-2025" has been added to ResearchAndMarkets.com's offering.This report contains a...
26 nov. 2025 07h04 HE | Source: Research and Markets

Vaccine Collaboration and Licensing Agreements Trends Analysis Report 2025 with Directory of 818 Deals Signed Since 2016 by Company A-Z, Therapy Focus and Technology Type

Dublin, Nov. 26, 2025 (GLOBE NEWSWIRE) -- The "Vaccine Collaboration and Licensing Deals 2016-2025" has been added to ResearchAndMarkets.com's offering.This report contains a comprehensive listing...

Page suivante